Latest Market Strategy News

Prophecy International Holdings reports a modest revenue dip and net loss in FY25, cancels its Complexica merger, and pivots to AI-driven product innovation and cost control.

Recce Pharmaceuticals has secured a key patent in Hong Kong for its synthetic anti-infectives, reinforcing its intellectual property footprint in Asia and supporting its clinical and commercial ambitions in the region.

Locksley Resources has kicked off its maiden drilling at the El Campo Rare Earths Prospect and secured full regulatory approval for an expanded program at the Desert Antimony Mine, setting the stage for continuous exploration updates through mid-2026.

Minbos Resources is advancing its Cabinda Phosphate and Capanda Green Ammonia projects with secured financing and construction underway, targeting first shipments in the first half of 2026. Strategic partnerships and government support underpin its ambitious plans to boost Angola’s agricultural and export sectors.

Proteomics International secures a key Medicare reimbursement rate for its PromarkerD test, a predictive diagnostic for diabetic kidney disease, marking a critical step in its US commercial rollout.

Lumos Diagnostics has achieved a major milestone by securing 100% Medicare reimbursement recognition for its FebriDx test across all seven US Medicare Administrative Contractors, paving the way for broader adoption in the American healthcare system.

Reece Limited reported a modest revenue decline and earnings pressure in FY25 amid challenging markets but reinforced its long-term growth strategy with a significant share buyback and board renewal. Early FY26 trading shows sales growth driven by network expansion despite ongoing cost pressures.

Reece Limited reported an 8% rise in first-quarter sales driven by network expansion, while profitability dipped due to higher costs and investments. The company also completed a $365 million share buyback, signaling confidence despite subdued market conditions.

HITIQ Limited has launched its PROTEQT™ concussion management system in North America, securing exclusive Canadian distribution rights and initiating a dual-channel market strategy targeting hockey’s vast ecosystem.

IPH Limited reported solid FY25 profit growth driven by Canadian acquisitions and a promising FY26 start despite challenges in Australia and New Zealand. CEO Andrew Blattman announced his retirement for late 2026, marking a pivotal leadership transition.

HeraMED has achieved a significant regulatory milestone with the Therapeutic Goods Administration upgrading its HeraBEAT fetal heart rate monitor to Class IIb, making it the only remote home-use device approved in Australia. This positions the company for a potentially lucrative expansion in the Australian maternity care market.

AFT Pharmaceuticals delivered a robust first half for FY26, posting 33% revenue growth and a return to profitability, driven by strong Australian sales and recovery in Asia and international markets. The company is advancing its global footprint and R&D pipeline, positioning for sustained growth.